SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX surged after clinical data for its obesity candidate VK2735 showed continued weight loss with weekly dosing and strong retention of prior weight loss on less-frequent maintenance injections, alongside encouraging tolerability. Traders largely viewed the results as strengthening the drugs competitive position and prompting analyst upgrades, while buyout and short-squeeze talk remained speculative and some questioned the move amid dilution concerns and competition.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs claimed real-time quantum error-correction decoder running on a standard CPU is driving discussion, with bullish traders viewing it as progress toward fault-tolerant systems and skeptics arguing the demonstration is simulation-based and overhyped. The announcement has prompted excitement about quantum-sector momentum alongside caution about whether the technology will scale in hardware.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtions quantum error-correction work integrating its qLDPC library with NVIDIA CUDA-Q Logical is drawing attention, with bulls viewing the collaboration as progress toward fault-tolerant computing. Traders are also frustrated that the stock has not responded consistently to the technical news, pointing to volatility and broader market conditions as counterweights.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBARs sharp rebound toward the 10-cent level is drawing attention, with traders highlighting a possible technical breakout while others see resistance and warn that past rallies have faded. The moves specific catalyst is unclear, and discussion also reflects broader uncertainty about crypto markets and the stalled CLARITY Act.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Cantor Fitzgeralds upgrade, based on a more optimistic view of Yartemleas commercial potential, is driving attention. Many traders welcomed the move, while others questioned whether the upgrade alone explains the surge and speculated about additional catalysts.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys first Alloy Kore design win, selected by Coretura for its software-defined commercial-vehicle platform, is drawing attention as a new QNX growth opportunity and a sizable addition to royalty backlog. Traders are largely bullish on the validation but debate how quickly it will translate into revenue, with many looking to upcoming earnings and guidance for confirmation amid frustration that the share-price response has been muted.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned Q4 BLA submission for CAN-2409 in localized prostate cancer is the dominant focus, with traders also watching upcoming biomarker data and manufacturing validation. Optimism over the positive Phase 3 results and managements on-track guidance is tempered by concerns that the timeline is tight, amplified by reaction to CEO Paul Peter Taks preplanned share sale.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias settlement with Teva, which delays generic voclosporin entry and recognizes the validity of key patents, is driving discussion, with traders viewing it as a boost to the companys position in ongoing cases against other generic makers. Many are bullish on further settlements and a potential buyout, though those outcomes remain speculative and some investors are frustrated by the muted, low-volume trading.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadus 180-day lockup expiration is the dominant focus, with traders attributing the sharp selloff to a large increase in shares available for trading and warning of continued selling pressure. Others view the drop as a buying opportunity, while concerns about dilution and the companys early-stage business remain.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

SLV is drawing attention as silver swings through a volatile consolidation, with traders weighing higher rates, Treasury yields and dollar strength against safe-haven demand and concerns about currency debasement and tight supply. Bulls view the pullback as an opportunity and point to silvers resilience, while bears warn that yield pressure could drive further weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BIO-Key Scores Portuguese National Security Deal

BIO-key (NASDAQ: BKYI) secures a tech deal with Visualforma for a Portuguese national security agency. Shares traded lower Monday.read more...

BIO-key Discloses Orders From A ‘Foreign Defense Ministry’ – BKYI Stock Gains 

Equity

The company, however, did not disclose the organization's name but stated that it currently supports more than 50,000 licensed users for the ministry. 

This Nano Cap Cybersecurity Stock Surged Over 70% In Pre-Market Today – What Is The Portugal Connection?

BIO-key International announced a partnership with Visualforma to expand advanced identity and access management across Portugal’s public sector.

Top Small Cap Stocks To Watch Now - November 9th

Spring Valley Acquisition, BIO-key International, Motorsport Games, Navitas Semiconductor, and Direxion Daily TSLA Bear 1X Shares are the five Small Cap stocks to watch today, according to...

Promising Small Cap Stocks To Add to Your Watchlist - November 8th

Spring Valley Acquisition, Ondas, BIO-key International, Motorsport Games, and Navitas Semiconductor are the five Small Cap stocks to watch today, according to MarketBeat's stock screener tool...

Promising Small Cap Stocks Worth Watching - November 7th

Spring Valley Acquisition, BIO-key International, Motorsport Games, Power Solutions International, Direxion Daily TSLA Bear 1X Shares, Navitas Semiconductor, and Direxion Daily META Bull 2X Shares...

Retail Chatter On Bio-key Spikes 2,500% After Identity And Access Management Solutions Company Regains Nasdaq Compliance

Following the filing of the annual report on Form 10-K for the year ended Dec. 31, 2024 on Wednesday, the company has now regained compliance.


• Reported GAAP EPS of -$0.56 up 72.14% YoY
• Reported revenue of $1.92M up 13.15% YoY

Bio-Key International faces significant going concern risks driven by a history of losses, insufficient cash for twelve months of operations, and substantial inventory reserves from delayed projects in Nigeria.

Bio-Key International achieved 53% growth in quarterly license revenue, expanded its channel alliance program to over eighty-five participants, and strengthened its liquidity position through a $2.5 million warrant exercise.

BIO-key International, Inc. engages in the provision of an identity and access management platform. The firm's products include PortalGuard, Admin Panel, Hardware, Identity-Bound Biometrics, and MobileAuth. It offers its services to the education, finance, government, healthcare, manufacturing, and retail industries. The company was founded on January 7, 1993 and is headquartered in Holmdel, NJ.

Bio-Key International Inc.

Bullish Sentiment

Job displacement

Market bubble / overvaluation

Loss of human oversight / control

Killer robots 🤖

As AI spending accelerates across hyperscalers and valuations climb to historic highs, investors and workers alike are increasingly debating the risks the technology poses - from job displacement to fears about losing human oversight over increasingly autonomous systems. What do you think is the biggest threat AI poses? Vote and explain your reasoning in the comments.

Current Price	$2.38
Prev Close	$2.47
Open	$2.51
Dividend Yield	0.00%
50-Day Moving Average	$3.58
Beta	-0.59
Avg. Volume	76,045.25
PE Ratio	-0.61

52-Week High	$197.00
52-Week Low	$2.40
Market Capitalization	$3.55M
EPS (Annual)	-$10.77
Price to Book	0.62
Revenue Per Employee	$141,370.36

Feed

News

Sentiment

Earnings

Fundamentals

Info

BKYI Fundamentals